US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% SNDK $1,719.99 ▲+0.00% TSLA $370.59 ▲+0.00% SDEV $7.48 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Climb Bio, Inc. - Common Stock (NQ:CLYM)

10.94 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Climb Bio, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Friday? ↗
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Top movers in Thursday's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Friday's after hours session: top gainers and losers ↗
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to be Added to the Nasdaq Biotechnology Index
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Host Virtual Investor Event on October 15, 2024
From Climb Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >